Antithrombotic Therapy
8
3
3
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
50%
4 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (8)
Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI
STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump
Protocol-based Management and Perioperative Outcomes in Patients With Chronic Antithrombotic Therapy
Endoscopic Evaluation for Iron Deficiency Anemia in Patients on Antithrombotic Therapy
Assessing the Effectiveness and Safety of Pericapsular Nerve Group (PENG) Block in Hip Fracture Patients on Antithrombotic Therapy
Apixaban for the Prevention of Latent Biological Valve Thrombosis
Antithrombotic Strategy Based on Clinical Events and 4D-CT for Patients After TAVR
Rivaroxaban in Patients With Atrial Fibrillation Undergoing PCI